Inozyme Pharma, Inc. Board of Directors

Inozyme Pharma, Inc., a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.

Dr. Demetrios Braddock M.D., Ph.D.

Dr. Demetrios Braddock M.D., Ph.D.

Co-Founder, Scientific Founder, Member of Scientific Advisory Board & Board Observer

Mr. Stefan Riley

Mr. Stefan Riley

Director of Investor Relations

Mr. Axel Bolte M.B.A., M.Sc.

Mr. Axel Bolte M.B.A., M.Sc.

Co-Founder, Senior Advisor & Director

Mr. Sanjay S. Subramanian M.B.A., M.S.

Mr. Sanjay S. Subramanian M.B.A., M.S.

Senior VP, CFO, Principal Accounting Officer & Corporate Secretary

Dr. Soojin Kim Ph.D.

Dr. Soojin Kim Ph.D.

Senior VP & Chief Technical Operations Officer

Dr. Yves Sabbagh Ph.D.

Dr. Yves Sabbagh Ph.D.

Chairman of Scientific Advisory Board & Senior VP

Ms. Gayle Gironda

Ms. Gayle Gironda

Senior VP & Chief People Officer

Leaving Board of Directors Review Your about to visit the following url Invalid URL

Loading...
Comments


Comment created.